(Q44539646)

4 December 2017

title

The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells (English)

1 reference

4 December 2017

1 reference

6

Craig B Thompson

1 reference

4 December 2017

Thomas R Johnson

1

1 reference

4 December 2017

Kimberley Stone

2

1 reference

4 December 2017

Malti Nikrad

3

1 reference

4 December 2017

Tammie Yeh

4

1 reference

4 December 2017

Wei-Xing Zong

5

1 reference

4 December 2017

Alexandre Nesterov

7

1 reference

4 December 2017

Andrew S Kraft

8

1 reference

4 December 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

4 December 2017

1 reference

4 December 2017

volume

22

1 reference

4 December 2017

issue

32

1 reference

4 December 2017

page(s)

4953-4963

1 reference

Bax and Bak independently promote cytochrome C release from mitochondria

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206656

The role of NF-kappa B in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206656

Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206656

Bile acids stimulate cFLIP phosphorylation enhancing TRAIL-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206656

An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206656

Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206656

Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206656

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206656

Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206656

Activation of caspase-3 alone is insufficient for apoptotic morphological changes in human neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206656

Differential modulation of apoptosis sensitivity in CD95 type I and type II cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206656

Inhibition of death receptor-mediated gene induction by a cycloheximide-sensitive factor occurs at the level of or upstream of Fas-associated death domain protein (FADD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206656

Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206656

Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206656

7 January 2021

Quantitative HOX expression in chromosomally defined subsets of acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206656

7 January 2021

Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression.

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206656

7 January 2021

Differential requirement for caspase 9 in apoptotic pathways in vivo.

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206656

7 January 2021

Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206656

7 January 2021

Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206656

7 January 2021

Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206656

7 January 2021

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206656

7 January 2021

TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2.

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206656

7 January 2021

Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype.

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206656

7 January 2021

Bcl-2 oncoprotein protects the human prostatic carcinoma cell line PC3 from TRAIL-mediated apoptosis.

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206656

7 January 2021

NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206656

7 January 2021

Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death

1 reference

https://api.crossref.org/works/10.1038/SJ.ONC.1206656

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1206656

1 reference

4 December 2017

1 reference